Safety
headache, nosebleed, rash, nasal blockage
APHTHOUS ULCERS, ADVERSE EVENT, NOSEBLEED
Adverse events occurred in both groups and were mild. Patients expressed symptoms such as nasal blockage, nasal drip, sneezing, and difficulty breathing while exercising, in both groups. One patient in the placebo group had a severe headache, another received a rash on the stomach and back and experienced trouble falling asleep. The symptoms resolved within a day. In the treated group two patients expressed problems with nosebleed, one became sensitive to light, another experienced trouble falling asleep and had nightmares and one got aphthous ulcers. The symptoms resolved within one to three days. No SAE were reported during the study period.All patients where within the reference interval both before- and after trial start when analysing ACTH and bone turnover marker CTx (see supplement Tables 